The HIV wasting syndrome.
Reiter
G S
GS
Tufts University, School of Medicine, Boston, MA.
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control; D000273:Adipose Tissue / Q000503:physiopathology; D045930:Anabolic Agents / Q000627:therapeutic use; D000728:Androgens / Q000172:deficiency; D019380:Anti-HIV Agents / Q000627:therapeutic use; D013759:Dronabinol / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D019247:HIV Wasting Syndrome / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008297:Male; D019290:Megestrol Acetate / Q000627:therapeutic use; D009132:Muscles / Q000503:physiopathology; D009369:Neoplasms / Q000139:chemically induced; D019966:Substance-Related Disorders
D045930:Anabolic Agents; D000728:Androgens; D019380:Anti-HIV Agents; D013759:Dronabinol; D019290:Megestrol Acetate